カルナバイオサイエンスの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2018/09/28 | 1,515 | 1,539 | 1,499 | 1,534 | +10 | +0.7% | 80,300 |
2018/09/27 | 1,521 | 1,604 | 1,507 | 1,524 | -20 | -1.3% | 199,400 |
2018/09/26 | 1,444 | 1,548 | 1,444 | 1,544 | +100 | +6.9% | 168,900 |
2018/09/25 | 1,471 | 1,481 | 1,435 | 1,444 | -27 | -1.8% | 114,500 |
2018/09/21 | 1,490 | 1,511 | 1,467 | 1,471 | -18 | -1.2% | 133,900 |
2018/09/20 | 1,392 | 1,696 | 1,385 | 1,489 | +93 | +6.7% | 898,800 |
2018/09/19 | 1,384 | 1,405 | 1,376 | 1,396 | -5 | -0.4% | 53,300 |
2018/09/18 | 1,398 | 1,414 | 1,384 | 1,401 | +3 | +0.2% | 36,000 |
2018/09/14 | 1,382 | 1,407 | 1,370 | 1,398 | +16 | +1.2% | 46,000 |
2018/09/13 | 1,363 | 1,391 | 1,363 | 1,382 | +15 | +1.1% | 37,000 |
2018/09/12 | 1,401 | 1,405 | 1,364 | 1,367 | -29 | -2.1% | 56,600 |
2018/09/11 | 1,396 | 1,407 | 1,363 | 1,396 | +4 | +0.3% | 73,400 |
2018/09/10 | 1,427 | 1,439 | 1,392 | 1,392 | -35 | -2.5% | 76,300 |
2018/09/07 | 1,441 | 1,441 | 1,405 | 1,427 | -31 | -2.1% | 58,600 |
2018/09/06 | 1,485 | 1,494 | 1,445 | 1,458 | -29 | -2% | 55,300 |
2018/09/05 | 1,500 | 1,530 | 1,480 | 1,487 | -21 | -1.4% | 69,400 |
2018/09/04 | 1,572 | 1,573 | 1,505 | 1,508 | -63 | -4% | 138,700 |
2018/09/03 | 1,561 | 1,601 | 1,561 | 1,571 | -30 | -1.9% | 85,900 |
2018/08/31 | 1,595 | 1,605 | 1,575 | 1,601 | +5 | +0.3% | 52,900 |
2018/08/30 | 1,603 | 1,609 | 1,571 | 1,596 | -12 | -0.7% | 88,200 |
2018/08/29 | 1,617 | 1,632 | 1,595 | 1,608 | -2 | -0.1% | 69,300 |
2018/08/28 | 1,626 | 1,646 | 1,569 | 1,610 | +14 | +0.9% | 253,700 |
2018/08/27 | 1,532 | 1,600 | 1,532 | 1,596 | +64 | +4.2% | 113,000 |
2018/08/24 | 1,510 | 1,548 | 1,510 | 1,532 | +28 | +1.9% | 181,300 |
2018/08/23 | 1,456 | 1,506 | 1,456 | 1,504 | +49 | +3.4% | 77,100 |
2018/08/22 | 1,421 | 1,470 | 1,421 | 1,455 | +39 | +2.8% | 40,600 |
2018/08/21 | 1,427 | 1,446 | 1,412 | 1,416 | -15 | -1% | 29,400 |
2018/08/20 | 1,424 | 1,459 | 1,408 | 1,431 | +34 | +2.4% | 33,800 |
2018/08/17 | 1,394 | 1,428 | 1,383 | 1,397 | +7 | +0.5% | 38,600 |
2018/08/16 | 1,390 | 1,404 | 1,377 | 1,390 | -13 | -0.9% | 25,300 |
2018/08/15 | 1,457 | 1,460 | 1,390 | 1,403 | -42 | -2.9% | 59,800 |
2018/08/14 | 1,387 | 1,457 | 1,387 | 1,445 | +56 | +4% | 47,700 |
2018/08/13 | 1,472 | 1,473 | 1,389 | 1,389 | -83 | -5.6% | 94,900 |
2018/08/10 | 1,384 | 1,589 | 1,384 | 1,472 | +91 | +6.6% | 345,200 |
2018/08/09 | 1,380 | 1,388 | 1,361 | 1,381 | -3 | -0.2% | 14,700 |
2018/08/08 | 1,351 | 1,390 | 1,350 | 1,384 | +21 | +1.5% | 43,000 |
2018/08/07 | 1,414 | 1,440 | 1,350 | 1,363 | -74 | -5.1% | 88,500 |
2018/08/06 | 1,458 | 1,477 | 1,430 | 1,437 | -24 | -1.6% | 35,500 |
2018/08/03 | 1,467 | 1,494 | 1,460 | 1,461 | -23 | -1.5% | 51,900 |
2018/08/02 | 1,440 | 1,487 | 1,430 | 1,484 | +45 | +3.1% | 60,900 |
2018/08/01 | 1,454 | 1,467 | 1,436 | 1,439 | -24 | -1.6% | 34,100 |
2018/07/31 | 1,400 | 1,468 | 1,383 | 1,463 | +50 | +3.5% | 56,600 |
2018/07/30 | 1,453 | 1,453 | 1,402 | 1,413 | -40 | -2.8% | 53,900 |
2018/07/27 | 1,450 | 1,470 | 1,430 | 1,453 | +10 | +0.7% | 53,200 |
2018/07/26 | 1,430 | 1,447 | 1,414 | 1,443 | +8 | +0.6% | 42,500 |
2018/07/25 | 1,410 | 1,436 | 1,407 | 1,435 | +32 | +2.3% | 49,400 |
2018/07/24 | 1,410 | 1,414 | 1,381 | 1,403 | -7 | -0.5% | 28,000 |
2018/07/23 | 1,393 | 1,418 | 1,384 | 1,410 | +21 | +1.5% | 56,500 |
2018/07/20 | 1,354 | 1,389 | 1,347 | 1,389 | +20 | +1.5% | 45,900 |
2018/07/19 | 1,361 | 1,374 | 1,346 | 1,369 | +17 | +1.3% | 42,900 |
1501~
1550
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「カルナバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
カルナバイオ | 31,000円 | -43.1% | - | 0.00% | - | 1.84倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
ノイルイミューン | 17,300円 | -97.8% | - | 0.00% | - | 1.50倍 |
|
独自技術用いたCAR-T細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
日ケミファ | 151,100円 | +2.5% | - | 3.31% | 90.86倍 | 0.29倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
VIS | 89,000円 | +87.8% | +265.7% | 0.00% | 53.45倍 | 2.45倍 |
|
mRNA標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
クリングル | 84,500円 | +240.0% | - | 0.00% | - | 2.75倍 |
|
細胞の増殖、保護、修復などの機能があるHGFタンパク質を用いて、難治性疾患治療薬を開発 |
市場注目の銘柄
チャート関連のコラム